TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 28786323

Group type: COMPARATOR
Intervention: Advance care planning with family carers, including a trained facilitator, family education, family meetings, documentation of advance care planning decisions, and intervention orientation for general practitioners and nursing home staff.
Number of subjects: 24
Study: 26104968

Group type: EXPERIMENTAL
Intervention: Sleep restriction (SR)
Number of subjects: 22

Group type: COMPARATOR
Intervention: Habitual sleep (HS)
Number of subjects: 22
Study: 24714773

Group type: EXPERIMENTAL
Intervention: Catumaxomab
Number of subjects: 245

Group type: COMPARATOR
Intervention: Paracentesis alone
Number of subjects: 245
Study: 23515883

Group type: EXPERIMENTAL
Intervention: Remote monitoring (RM)
Number of subjects: 233

Group type: COMPARATOR
Intervention: Conventional in-hospital visits
Number of subjects: 233
Study: 20437350

Group type: EXPERIMENTAL
Intervention: Novel hemostatic devices
Number of subjects: 195

Group type: COMPARATOR
Intervention: Classic suture ligation technique
Number of subjects: 195
Study: 18410803

Group type: EXPERIMENTAL
Intervention: Day cream with photostable combination of UVB and UVA filters
Number of subjects: 12
Study: 16606638

Group type: EXPERIMENTAL
Intervention: Printed brochure and electronic newsletters (print group)
Number of subjects: 963

Group type: EXPERIMENTAL
Intervention: Radio advertisements (radio group)
Number of subjects: 963

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 963
Study: 12697135

Group type: EXPERIMENTAL
Intervention: Levetiracetam (LEV)
Number of subjects: 101

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 101
Study: 10894871

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF) - 6 cycles; Cyclophosphamide 100 mg/m² orally days 1 to 14, Methotrexate 40 mg/m² IV days 1 and 8, Fluorouracil 600 mg/m² IV days 1 and 8
Number of subjects: 244

Group type: COMPARATOR
Intervention: Tamoxifen plus ovarian suppression (5 years of tamoxifen 30 mg/d, plus surgical oophorectomy, ovarian irradiation, or monthly goserelin 3.6 mg injections)
Number of subjects: 244

Group type: EXPERIMENTAL
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 244

Group type: COMPARATOR
Intervention: Tamoxifen plus ovarian suppression
Number of subjects: 244
Study: 9366929

Group type: EXPERIMENTAL
Intervention: Pancuronium
Number of subjects: 691

Group type: COMPARATOR
Intervention: Atracurium/Vecuronium
Number of subjects: 691
Study: 8507018

Group type: EXPERIMENTAL
Intervention: 0.2 mg/kg nalbuphine
Number of subjects: 24

Group type: COMPARATOR
Intervention: 2 micrograms/kg fentanyl
Number of subjects: 24
Study: 3877474

Group type: EXPERIMENTAL
Intervention: 1.5 mg/kg propofol
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 2 mg/kg propofol
Number of subjects: 30

Group type: COMPARATOR
Intervention: 4 mg/kg thiopentone
Number of subjects: 30
Study: 30301555

Group type: EXPERIMENTAL
Intervention: Intralesional MA (≥175 μm greatest linear dimension of choroidal vessels seen on FA and/or color, aided by OCT) in study eyes.
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Study eyes with ≥50% classic CNV at baseline.
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Study eyes with subretinal fluid at final visit.
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Study eyes with pigment epithelial detachment at final visit.
Number of subjects: 594

Group type: EXPERIMENTAL
Intervention: Fellow eyes with baseline intralesional MA.
Number of subjects: 594
Study: 29655626

Group type: EXPERIMENTAL
Intervention: 3+1 (PCV7 booster after 3 priming doses)
Number of subjects: 544

Group type: EXPERIMENTAL
Intervention: 3+0 (3 doses of PCV7)
Number of subjects: 544

Group type: COMPARATOR
Intervention: 0+2 (control group, 12 and 18 months doses)
Number of subjects: 544
Study: 27038451

Group type: EXPERIMENTAL
Intervention: Exenatide (n=24)
Number of subjects: 52

Group type: COMPARATOR
Intervention: Placebo (n=28)
Number of subjects: 52
Study: 25518508

Group type: EXPERIMENTAL
Intervention: Cytoflavin (2 tablets b.i.d. on days 1 to 25) during standard basic therapy
Number of subjects: 140

Group type: COMPARATOR
Intervention: Standard basic therapy only
Number of subjects: 140

Group type: COMPARATOR
Intervention: Control group (30 apparently healthy individuals)
Number of subjects: 140
Study: 21743402

Group type: EXPERIMENTAL
Intervention: OralCDx® brush biopsy technique
Number of subjects: 24

Group type: COMPARATOR
Intervention: Conventional biopsy using a surgical scalpel
Number of subjects: 24
Study: 20136785

Group type: EXPERIMENTAL
Intervention: Alemtuzumab (single dose)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Basiliximab (nondepleting protocol)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 0
Study: 18514671

Group type: EXPERIMENTAL
Intervention: Epithane‐3 (E3)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Secure(2) Medical Adhesive (SMA)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Skin-Prep Protective Dressing (SP)
Number of subjects: 26

Group type: COMPARATOR
Intervention: No Skin-Prep Protective Dressing (no SP)
Number of subjects: 26
Study: 15805318

Group type: EXPERIMENTAL
Intervention: Ultrasound treatment followed by 5 minutes of 4% liposomal lidocaine cream
Number of subjects: 87

Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 87
Study: 12740454

Group type: EXPERIMENTAL
Intervention: TM-based, cognitive-behavioral intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Enhanced usual care
Number of subjects: 0

Group type: COMPARATOR
Intervention: Single-item algorithms
Number of subjects: 0
Study: 11420886

Group type: EXPERIMENTAL
Intervention: ARTEM (300 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: MQ (750 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: QN (600 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: PQ (45 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ARTEM (300 mg) + MQ (750 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ARTEM (300 mg) + QN (600 mg)
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: ARTEM (300 mg) + PQ (45 mg)
Number of subjects: 8
Study: 8785189

Group type: EXPERIMENTAL
Intervention: Alcohol addition (23% energy as alcohol)
Number of subjects: 11

Group type: EXPERIMENTAL
Intervention: Alcohol substitution (alcohol replacing 23% of carbohydrate energy)
Number of subjects: 11

Group type: COMPARATOR
Intervention: Control (50% of maintenance energy needs)
Number of subjects: 11
Study: 1814866

Group type: EXPERIMENTAL
Intervention: Noise at 100 dB (A) and heat at 35 degrees C
Number of subjects: 24

Group type: COMPARATOR
Intervention: Noise at 70 dB (A) and heat at 28 degrees C
Number of subjects: 24
Study: 6721271

Group type: EXPERIMENTAL
Intervention: Budesonide 400 micrograms/day with spacer
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Budesonide 1600 micrograms/day with spacer
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Budesonide with spacer
Number of subjects: 35
Study: 31444564

Group type: EXPERIMENTAL
Intervention: Suture-only technique (Group A)
Number of subjects: 29

Group type: EXPERIMENTAL
Intervention: Suture-only technique with capsulodesis (Group B)
Number of subjects: 29
Study: 29047384

Group type: EXPERIMENTAL
Intervention: Dissemination strategies including multi-day in-person workshops, electronic information exchange methods, technical assistance through a knowledge broker, and organizational changes to support evidence-based public health approaches.
Number of subjects: 12

Group type: COMPARATOR
Intervention: Usual practice (control group)
Number of subjects: 12
Study: 25672892

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D (1,000 mg calcium carbonate and 400 IU vitamin D3 per day)
Number of subjects: 36282

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36282

Group type: EXPERIMENTAL
Intervention: Calcium plus vitamin D
Number of subjects: 36282
Study: 24491192

Group type: EXPERIMENTAL
Intervention: Positive parenting strategies during safe driving and risky driving
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Negative feedback during risky driving
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Parenting behaviors during driving
Number of subjects: 0
Study: 22420109

Group type: EXPERIMENTAL
Intervention: Anchoring-point messages
Number of subjects: 0

Group type: COMPARATOR
Intervention: Messages without anchoring points
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Higher anchoring point messages (speeding mortality)
Number of subjects: 0
Study: 18231120

Group type: EXPERIMENTAL
Intervention: Daily supplementation of vitamin D drops containing 10 microg (400 IU) of ergocalciferol (vitamin D(2)) with information brochure
Number of subjects: 66

Group type: EXPERIMENTAL
Intervention: Daily supplementation of vitamin D drops
Number of subjects: 66

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 66
Study: 17605698

Group type: EXPERIMENTAL
Intervention: Mums and Babies program (MB group)
Number of subjects: 0

Group type: COMPARATOR
Intervention: PreMB group (historical control)
Number of subjects: 0
Study: 15479314

Group type: EXPERIMENTAL
Intervention: Epidural analgesia and cryoanalgesia combined
Number of subjects: 90

Group type: COMPARATOR
Intervention: Epidural analgesia alone
Number of subjects: 90
Study: 11409564

Group type: EXPERIMENTAL
Intervention: Rifampicin-ciprofloxacin
Number of subjects: 1
Study: 9399276

Group type: EXPERIMENTAL
Intervention: Infusion rate (rapid infusion)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Infusion rate (two rates studied in vivo)
Number of subjects: 26

Group type: EXPERIMENTAL
Intervention: Rapid infusion rate
Number of subjects: 26
Study: 7957526

Group type: EXPERIMENTAL
Intervention: 5-Methoxypsoralen (5-MOP) with food
Number of subjects: 9

Group type: COMPARATOR
Intervention: 5-Methoxypsoralen (5-MOP) under fasting conditions
Number of subjects: 9
Study: 3115780

Group type: EXPERIMENTAL
Intervention: 200 mg day‐1 of flecainide
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: 300 mg day‐1 of flecainide
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Severe cardiac adverse effects
Number of subjects: 36
Study: 28623471

Group type: EXPERIMENTAL
Intervention: IV lidocaine (1.5 mg kg−1 bolus then 1 mg kg−1 per hour)
Number of subjects: 25
Study: 28232170

Group type: EXPERIMENTAL
Intervention: Ketamine (target plasma level=100ng/ml)
Number of subjects: 21
Study: 26369798

Group type: EXPERIMENTAL
Intervention: Intravitreal aflibercept injections
Number of subjects: 220

Group type: COMPARATOR
Intervention: PRP (panretinal photocoagulation)
Number of subjects: 220
Study: 23404063

Group type: EXPERIMENTAL
Intervention: Stress before reactivation (exp 1)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Stress before reconsolidation (exp 2)
Number of subjects: 0
Study: 21328373

Group type: EXPERIMENTAL
Intervention: Entecavir (ETV), n=13
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Adefovir dipivoxil (ADV), n=22
Number of subjects: 35

Group type: COMPARATOR
Intervention: Placebo, n=14
Number of subjects: 35

Group type: EXPERIMENTAL
Intervention: Overall treatment (ETV or ADV)
Number of subjects: 35
Study: 19548415

Group type: EXPERIMENTAL
Intervention: Optosil/Xantopren L (Heraeus Kulzer)
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Experimental ultralight body/putty material (3M ESPE)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Express STD Putty/Wash (3M ESPE)
Number of subjects: 24
Study: 17540210

Group type: EXPERIMENTAL
Intervention: Exercise training (2-month residential rehabilitation program)
Number of subjects: 24

Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 24
Study: 15169686

Group type: EXPERIMENTAL
Intervention: Olanzapine (mean modal dose= 9.63 mg/day)
Number of subjects: 167

Group type: COMPARATOR
Intervention: Haloperidol (mean modal dose=4.60 mg/day)
Number of subjects: 167

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 167

Group type: COMPARATOR
Intervention: Haloperidol
Number of subjects: 167
Study: 11354595

Group type: EXPERIMENTAL
Intervention: Competitive employment at baseline (10%)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Patients not competitively employed at baseline who reported interest in working (61%)
Number of subjects: 528

Group type: EXPERIMENTAL
Intervention: Correlates of work at followups
Number of subjects: 528
Study: 9845936

Group type: EXPERIMENTAL
Intervention: Naltrexone administered prophylactically for 6 months or longer
Number of subjects: 120

Group type: COMPARATOR
Intervention: Control group (no naltrexone)
Number of subjects: 120
Study: 8919632

Group type: EXPERIMENTAL
Intervention: Amlodipine 5 mg by single daily administration (Group A)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Amlodipine 10 mg for the first 3 days, then 5 mg thereafter (Group B)
Number of subjects: 18
Study: 2184654

Group type: EXPERIMENTAL
Intervention: Indapamide alone (group I)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Indapamide in combination with captopril (group II)
Number of subjects: 120

Group type: EXPERIMENTAL
Intervention: Indapamide in combination with propranolol (group III)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Placebo (during 2-week run-in period)
Number of subjects: 120
Study: 6110803

Group type: EXPERIMENTAL
Intervention: Camazepam 40 mg
Number of subjects: 12
Study: 30758095

Group type: EXPERIMENTAL
Intervention: Friendship groups with higher average depressive symptoms
Number of subjects: 3013

Group type: EXPERIMENTAL
Intervention: Friendship groups with higher average anxiety symptoms
Number of subjects: 3013

Group type: EXPERIMENTAL
Intervention: Friendship groups with greater variability in depressive symptoms
Number of subjects: 3013

Group type: EXPERIMENTAL
Intervention: Friendship groups with greater variability in anxiety symptoms
Number of subjects: 3013
Study: 31196156

Group type: EXPERIMENTAL
Intervention: ADAPT intervention involving a multidisciplinary team (registered nurse, social worker, palliative care specialist, primary care provider) with six visits to manage symptoms and psychosocial interventions.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: ADAPT intervention
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 25827253

Group type: EXPERIMENTAL
Intervention: Home-based, self-directed physical activity intervention
Number of subjects: 40

Group type: COMPARATOR
Intervention: Usual care (Control)
Number of subjects: 40
Study: 26099241

Group type: COMPARATOR
Intervention: No comorbidity
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: One comorbidity
Number of subjects: 79

Group type: EXPERIMENTAL
Intervention: Two or three comorbidities
Number of subjects: 79
Study: 23159427

Group type: EXPERIMENTAL
Intervention: Stylet use
Number of subjects: 46

Group type: COMPARATOR
Intervention: No stylet
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Inexperienced providers
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Experienced providers
Number of subjects: 46
Study: 21555779

Group type: EXPERIMENTAL
Intervention: Behavior therapy
Number of subjects: 126

Group type: COMPARATOR
Intervention: Control treatment
Number of subjects: 126
Study: 18451385

Group type: EXPERIMENTAL
Intervention: Orthopaedic surgeon ordering a bone mineral density examination and forwarding the results to the primary care physician
Number of subjects: 50

Group type: COMPARATOR
Intervention: Orthopaedic surgeon sending a letter to the primary care physician outlining guidelines for osteoporosis screening
Number of subjects: 50
Study: 16921035

Group type: EXPERIMENTAL
Intervention: VACA-IE (chemotherapy with doxorubicin, vincristine, cyclophosphamide, dactinomycin alternating with ifosfamide and etoposide)
Number of subjects: 75

Group type: COMPARATOR
Intervention: VACA (chemotherapy with doxorubicin, vincristine, cyclophosphamide, dactinomycin)
Number of subjects: 75
Study: 12669755

Group type: EXPERIMENTAL
Intervention: Cognitive priming
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sensory priming
Number of subjects: 0
Study: 11151399

Group type: EXPERIMENTAL
Intervention: Education and professional remuneration (Group B)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Advanced education and professional remuneration (Group C)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Control group (Group A)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Professional remuneration with no education (Group D)
Number of subjects: 30
Study: 9668534

Group type: EXPERIMENTAL
Intervention: Hydroxyurea
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Hydroxyurea + recombinant human erythropoietin
Number of subjects: 0
Study: 7919126

Group type: EXPERIMENTAL
Intervention: Ultrasound (US)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Computed Tomography (CT)
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Endoscopic Retrograde Cholangiopancreatography (ERCP)
Number of subjects: 33

Group type: COMPARATOR
Intervention: Comparison of US and ERCP
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: Overall conclusion
Number of subjects: 33
Study: 2840172

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 10 mg/kg body weight/day for 20 days
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 10 mg/kg body weight/day for 40 days
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 15 mg/kg body weight/day for 20 days
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 15 mg/kg body weight/day for 40 days
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 20 mg/kg body weight/day for 20 days
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 20 mg/kg body weight/day for 40 days
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 20 mg/kg for 40 days
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 20 mg/kg for 20 days
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 15 mg/kg for 40 days
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 15 mg/kg for 20 days
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 10 mg/kg for 40 days
Number of subjects: 371

Group type: EXPERIMENTAL
Intervention: Sodium stibogluconate 10 mg/kg for 20 days
Number of subjects: 371
Study: 31790546

Group type: EXPERIMENTAL
Intervention: Brief advice (about 1 minute) with the option to choose quit schedules (immediate or progressive)
Number of subjects: 1571
Study: 30287915

Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 293

Group type: COMPARATOR
Intervention: No adjuvant therapy
Number of subjects: 293
Study: 28595147

Group type: EXPERIMENTAL
Intervention: Risperidone
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Olanzapine
Number of subjects: 119

Group type: EXPERIMENTAL
Intervention: Molindone
Number of subjects: 119

Group type: COMPARATOR
Intervention: Control group (random assignment to different antipsychotic treatment)
Number of subjects: 119
Study: 26263433

Group type: EXPERIMENTAL
Intervention: modified whole blood (mWB)
Number of subjects: 59

Group type: COMPARATOR
Intervention: component blood products (COMP)
Number of subjects: 59

Group type: EXPERIMENTAL
Intervention: both mWB and COMP
Number of subjects: 59
Study: 23420065

Group type: EXPERIMENTAL
Intervention: Non-bridging external fixation (AO small fixator)
Number of subjects: 102

Group type: COMPARATOR
Intervention: Plate osteosynthesis (2.4 mm, Synthes)
Number of subjects: 102
Study: 21501692

Group type: EXPERIMENTAL
Intervention: CIC‐HFA 282 μg
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CIC‐HFA 148 μg
Number of subjects: 36

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: CIC‐HFA 282 μg and 148 μg
Number of subjects: 36
Study: 18440674

Group type: EXPERIMENTAL
Intervention: Plasmid pTHr DNA vaccine
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Modified vaccinia virus Ankara (MVA) vaccine
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 16550943

Group type: EXPERIMENTAL
Intervention: Oral prednisone for 2 weeks
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Intranasal budesonide after oral prednisone
Number of subjects: 78

Group type: EXPERIMENTAL
Intervention: Oral prednisone and intranasal budesonide
Number of subjects: 78

Group type: COMPARATOR
Intervention: Control group (no steroid treatment)
Number of subjects: 78
Study: 12520564

Group type: EXPERIMENTAL
Intervention: Coronary artery stenting
Number of subjects: 5806
Study: 10752812

Group type: EXPERIMENTAL
Intervention: Hygrobac‐Dar HME (n = 21)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Humid‐Vent HME (n = 20)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: Clear‐Thermal HME (n = 20)
Number of subjects: 61

Group type: COMPARATOR
Intervention: All groups
Number of subjects: 61
Study: 8884011

Group type: EXPERIMENTAL
Intervention: Sil-K
Number of subjects: 26

Group type: COMPARATOR
Intervention: Epiderm
Number of subjects: 26
Study: 7519702

Group type: EXPERIMENTAL
Intervention: Buspirone 5 mg
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: Buspirone 15 mg
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 2843316

Group type: COMPARATOR
Intervention: 1 mCi Gold-198
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: 5 mCi Gold-198
Number of subjects: 46
Study: 30782759

Group type: EXPERIMENTAL
Intervention: Genetic counsellor-led intervention incorporating a custom-designed communication aid
Number of subjects: 0
Study: 29355002

Group type: EXPERIMENTAL
Intervention: Acupuncture plus clomiphene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control acupuncture plus clomiphene
Number of subjects: 0

Group type: COMPARATOR
Intervention: Clomiphene alone
Number of subjects: 0
Study: 24329126

Group type: EXPERIMENTAL
Intervention: Reward-primed go/no-go task
Number of subjects: 216

Group type: COMPARATOR
Intervention: No reward priming in go/no-go task
Number of subjects: 216
Study: 22926890

Group type: EXPERIMENTAL
Intervention: Immediate stent removal (group A)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Leaving the stent in place (group B)
Number of subjects: 40
Study: 20655282

Group type: EXPERIMENTAL
Intervention: Base-out prism bar vergences
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Vergence facility (12 base-out/3 base-in binocular prism flippers for 1 minute)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 5 minutes viewing with 6 prism diopters of base-out prism
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Modified Thorington method for measuring near phoria
Number of subjects: 30
Study: 18362295

Group type: EXPERIMENTAL
Intervention: GH therapy for 1 year
Number of subjects: 14

Group type: COMPARATOR
Intervention: Baseline GHD adults
Number of subjects: 14